Fig 4. Incorporation of amino acid substitutions that eliminate TMDD with enhanced affinity for human FcRn to form ALXN1210 enhances PK and extends duration of action in a mouse model.

(A) PK of single 100 μg IV dose of either eculizumab without (■) and with (□) human C5, or ALXN1210 without (◆) and with (◇) human C5 in NOD-SCID mice (n = 8 per group). (B) Corresponding ex vivo classical pathway hemolytic activity in the presence of eculizumab or ALXN1210 and human C5 alone (●).